• Home
  • About IonChannelCentral

Ion channel News

Entries RSS | Comments RSS
  • Tags

    agonist amitiza Amlodipine Anesiva Angiotensin II AT1 antagonist AstraZeneca ca channel Calcium Channel chloride channel CIC-2 CIC2 cl channel Clevelox Clevidipine Cleviprex CV therapeutics Icagen Ion Channel KCa3.1 K Channel Licensing lidocaine lubiprostone Merck na channel Novartis phase II Potassium Channel preclinical Regulatory Research RU-0211 RU0211 Senicapoc Sodium channel SPI-0211 Sucampo takeda The Medicines Company TRPV1 UCB Vanilloid voltage gated VR1

Vertexs VX-770 improves lung function in cystic fibrosis

Posted on June 13, 2008 by crimsoncanary

Data presentes at the 31st European Cystic Fibrosis Society Meeting shows Vertex’s VX-770 to improve lung function in cystic fibrosis patients.

Filed under: Ion Channel | Tagged: CFTR, chloride channel, Chlorine channel, cl channel, Vertex

« AstraZeneca and Cellectricon collaborate on Dynaflow High Throughput Ion Channel Screening Merck Serono license Bionomics Kv1.3 ion channel program »

Leave a Reply

Click here to cancel reply.

  • Calendar

    • June 2008
      M T W T F S S
      « May   Jul »
       1
      2345678
      9101112131415
      16171819202122
      23242526272829
      30  
  • Blogroll

    • CrimsonCanary.com
    • IonChannelCentral
    • KinaseCentral
    • PharmaCompanyPipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer